No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients

BACKGROUND & AIMS: Treatment with the combination of ledipasvir and sofosbuvir for 12 weeks has been approved by the Food and Drug Administration for patients with genotype 1 hepatitis C virus (HCV) infection; some patients can be treated with an 8-week course. Guidelines recommend a 12-week tre...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Gastroenterol Hepatol
Päätekijät: Marcus, Julia L., Hurley, Leo B., Chamberland, Scott, Champsi, Jamila H., Gittleman, Laura C., Korn, Daniel G., Lai, Jennifer B., Lam, Jennifer O., Pauly, Mary Patricia, Quesenberry, Charles P., Ready, Joanna, Saxena, Varun, Seo, Suk, Witt, David J., Silverberg, Michael J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5962408/
https://ncbi.nlm.nih.gov/pubmed/29535057
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2018.03.003
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia